Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: Results from a multicenter study in Switzerland

European Neurology

Volumn 63, Issue 2, 2010, Pages 101-106

  Putzki, Norman ^a   Yaldizli, Özgür ^a   Bühler, Robert ^b   Schwegler, Guido ^c   Curtius, Daniela ^d   Tettenborn, Barbara ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Bürgerspital Solothurn ^*  (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

^d Biogen Idec International GmbH   (Switzerland)

Author keywords

Disease modifying treatment; Glatiramer acetate; Interferon ; Multiple sclerosis; Natalizumab; Treatment failure

Indexed keywords

BETA INTERFERON; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; RITUXIMAB;

ADULT; ARTICLE; CHRONIC DIARRHEA; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SWITZERLAND; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES; SWITZERLAND;

EID: 74249110981     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276400     Document Type: Article

References (20)

1. Polman CH, O'Connor PW, Havrdova E, et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
2. Yednock TA, Cannon C, Fritz L, et al: Prevention of experimental autoimmune encephalomyelitis by antibodies against 41 integrin. Nature 1992; 356: 63-66.
3. Yousry TA, Major EO, Ryschkewitsch C, et al: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-933.
4. European Medicine Agency (2006) http:// www.emea.europa.eu/humandocs/ PDFs/ EPAR/tysabri/H-603-en6.pdf.
5. Rudick RA, Stuart WH, Calabresi PA, et al: Natalizumab plus interferon 1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
6. Poser CM, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
7. McDonald WI, Compston A, Edan G, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
8. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E: Defining interferon response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555.
9. Sorensen PS, Tscherning T, Mathiesen HK, et al: Neutralizing antibodies hamper IFN bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 67: 1681-1683.
10. Kappos L, Bates D, Hartung HP, et al: Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6: 431-441.
11. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O: Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006; 13: 471-474.
12. Carra A, Onaha P, Luetic B, et al: Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing- remitting multiple sclerosis in Argentina. Eur J Neurol 2008; 15: 386-393.
13. Limmroth V, Putzki N: High-dose, frequently administered interferon. J Neurol Sci 2005; 15: 95-96.
14. Confavreux C, Vukusic S: Non-specific immunosuppressants in the treatment of multiple sclerosis. Clin Neurol Neurosurg 2004; 106: 263-269.
15. Rizvi SA, Agius MA: Current approved options for treating patients with multiple sclerosis. Neurology 2004; 63(suppl 6):S8-S14.
16. Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR: Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology 2007; 68: 1524-1528.
17. Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V: Natalizumab is effective as second-line therapy in the treatment of relapsing remitting MS. Eur J Neurol 2009; 16: 424-426.
18. Oturai AB, Koch-Henriksen N, Petersen T, et al: Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009; 16: 420-423.
19. Hutchinson M, Kappos L, Calabresi PA, et al: The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009; 256: 405-415.
20. Gold R, Jawad A, Miller DH, et al: Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 2007; 187: 156-158.